IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$9.40 USD
+1.75 (22.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.41 +0.01 (0.11%) 5:18 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for IGM Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -246.42 | -221.10 | -165.16 | -81.36 | -43.13 |
Depreciation/Amortization & Depletion | -0.86 | 3.36 | 5.11 | 1.00 | 0.29 |
Net Change from Assets/Liabilities | -6.69 | 155.17 | 6.45 | 2.05 | -5.02 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 61.74 | 56.72 | 29.27 | 11.01 | 2.75 |
Net Cash From Operating Activities | -192.23 | -5.85 | -124.34 | -67.30 | -45.12 |
Property & Equipment | -12.38 | -10.21 | -13.24 | -17.50 | -2.34 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 80.74 | -215.44 | 28.06 | 75.21 | -200.90 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 68.36 | -225.64 | 14.82 | 57.71 | -203.24 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 115.07 | 219.38 | 4.03 | 217.01 | 269.03 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 15.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -1.56 | -2.23 | -1.77 |
Net Cash from Financing Activities | 115.07 | 219.38 | 2.48 | 214.78 | 282.26 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -8.81 | -12.12 | -107.05 | 205.19 | 33.90 |
Cash at Beginning of Period | 121.92 | 134.04 | 241.08 | 35.89 | 1.99 |
Cash at End of Period | 113.11 | 121.92 | 134.04 | 241.08 | 35.89 |
Diluted Net EPS | -4.71 | -5.32 | -4.93 | -2.65 | -4.80 |
Fiscal Year End for IGM Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -246.42 | -185.72 | -123.73 | -59.31 |
Depreciation/Amortization & Depletion | NA | -0.86 | -1.06 | -0.96 | -0.82 |
Net Change from Assets/Liabilities | NA | -6.69 | -6.05 | -10.79 | -4.94 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 61.74 | 48.60 | 31.39 | 14.08 |
Net Cash From Operating Activities | NA | -192.23 | -144.22 | -104.10 | -51.00 |
Property & Equipment | NA | -12.38 | -10.93 | -7.85 | -3.94 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 80.74 | 93.98 | 71.35 | 73.76 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 68.36 | 83.05 | 63.50 | 69.82 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 115.07 | 114.67 | 70.03 | 0.08 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 115.07 | 114.67 | 70.03 | 0.08 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -8.81 | 53.49 | 29.42 | 18.90 |
Cash at Beginning of Period | NA | 121.92 | 121.92 | 121.92 | 121.92 |
Cash at End of Period | NA | 113.11 | 175.41 | 151.34 | 140.82 |
Diluted Net EPS | NA | -0.91 | -1.04 | -1.43 | -1.33 |